Trust in Calyx EDC based on decade-long relationship drives contract extension decision
Nottingham, England and Morrisville, NC – February 14, 2022 – Calyx, the eClinical and Regulatory solutions, and service provider relied on for solving complex data challenges in clinical research, announced today that a Top 20 specialty pharmaceutical company will continue to rely on Calyx’s electronic data capture (EDC) system for a series of upcoming, early phase studies.
The Top 20 specialty pharmaceutical company is furthering its commitment to the relationship it has formed with Calyx and extending its use of the EDC system in multiple additional studies scheduled to begin this year. The company ‒ which has relied on Calyx EDC for over a decade ‒ will use the proven, robust system to capture important clinical trial data in early phase studies of new compounds being developed for diabetes, obesity, and NASH.
“We are so proud of the trust this Top 20 specialty pharmaceutical company places in Calyx EDC and we are delighted to continue supporting their efforts to bring advanced treatment options to the many people living with metabolic disorders and other diseases around the world,” said Juan Munoz-Pujol, Vice President, IRT and EDC at Calyx.
Click here for more information on Calyx EDC.
Through innovative eClinical and Regulatory solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market reliably. With deep expertise in clinical development and more than 25 years supporting trial sponsors and clinical research organizations, Calyx harnesses its intelligence and experience to solve complex problems, deliver fast insights, and get new drugs to market every day.
Christine Tobin | Christine.Tobin@Calyx.ai | +1 412-628-8598